FDA
-
-
-
-
-
-
-
Cue Biopharma licenses anti-IgE antibody in $691.5 million deal
-
-
-
-
-
-
-
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
-
-
-
-
-
-
-
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
-
-
-
-
-
-
-
Cue Biopharma names Usman Azam as new CEO effective September 29
-
-
-
-
-
-
-
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
-
-
-
-
-
-
-
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
-
326,541 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

